EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies utilizing tumor-derived extracellular vesicles (TEVs). This proprietary platform delivers immune-stimulating neoantigens to activate T cells and overcome resistance to checkpoint inhibitors. The company aims to enhance cancer treatment efficacy for patients unresponsive to current therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Checkpoint inhibitors are ineffective in over 85% of metastatic colorectal cancer cases, particularly in patients with the microsatellite stable (MSS) subtype, representing a significant unmet medical need. As cancer progresses, patients' T cells become desensitized and weakened, rendering checkpoint inhibitors unresponsive.
Solution
EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies derived from modified tumor-derived extracellular vesicles (mTEVs) to modulate and boost a patient's immune system. These therapeutic vaccines deliver a broad spectrum of immune-stimulating neoantigens without immune-suppressing factors, unlocking T cell costimulatory function (CD28) and enabling T cell activation, proliferation, and migration into the tumor microenvironment. This approach aims to restore the natural immune function and enhance cancer treatment efficacy, both as a monotherapy and in combination with checkpoint inhibitors, offering a potential solution for patients who no longer benefit from chemotherapy.
Target Audience
The primary target audience includes patients with advanced-stage metastatic colorectal and esophageal cancers, particularly those with the MSS subtype who do not respond to checkpoint inhibitors, as well as the physicians treating them.
Features
- Utilizes modified tumor-derived extracellular vesicles (mTEVs) to deliver neoantigens.
- Designed to unlock T cell costimulatory function (CD28) for enhanced T cell activation.
- Formulated as off-the-shelf therapeutic vaccines for convenient administration.
- Demonstrates pre-clinical efficacy across solid tumor and advanced metastatic animal models.
- Can be used as a monotherapy or in combination with checkpoint inhibitors.